Yamamoto Naoyuki, Ejiri Masahiro, Mizuno Seiichi
R&D center, Calpis Co., Ltd., 11-10, 5-Chome, Fuchinobe, Sagamihara, Kanagawa 229, Japan.
Curr Pharm Des. 2003;9(16):1345-55. doi: 10.2174/1381612033454801.
This paper reviews bioactive peptides, biogenic peptides, opioid peptides, immunostimulating peptides, mineral soluble peptides, antihypertensive peptides and antimicrobial peptides originating from food materials and enzymatic hydrolysis of proteins. Antihypertensive peptides are extensively reviewed and have been divided into angiotensin I-converting enzyme inhibitory peptides and others. These peptides are produced in the enzymatic hydrolysate of treated food materials such as milk, animal and fish meat, maize, wheat, soybeans and egg, and also from microbe-fermented products. Peptides with strong antihypertensive effects on spontaneously hypertensive rats are discussed and are divided into high and low angiotensin I-converting enzyme inhibitory activities. In addition, new topics from our studies on antihypertensive peptides are introduced. Efficacies of these peptides in clinical studies and differences with medicinal substances are summarized. Recent studies in this area shown the possibility of using biogenic peptides for improvements in treatment or prevention of hypertension.
本文综述了源自食品原料和蛋白质酶解的生物活性肽、生物源肽、阿片肽、免疫刺激肽、矿物可溶性肽、降压肽和抗菌肽。对降压肽进行了广泛综述，并将其分为血管紧张素I转换酶抑制肽和其他类型。这些肽产生于经处理的食品原料（如牛奶、畜禽肉、鱼肉、玉米、小麦、大豆和鸡蛋）的酶解产物中，也产生于微生物发酵产品中。讨论了对自发性高血压大鼠具有强降压作用的肽，并根据血管紧张素I转换酶抑制活性的高低进行了分类。此外，还介绍了我们关于降压肽研究的新课题。总结了这些肽在临床研究中的功效以及与药物的差异。该领域的最新研究表明，使用生物源肽改善高血压治疗或预防具有可能性。
